Seasonal Influenza Vaccine Market Size, Country Outlook, Vaccination Analysis, Pipeline Insights, Clinical Trials Statement, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast,2016 to 2022
Seasonal influenza is a grave public health issue which causes serious illness and death in densely populated regions. It is an acute viral infection caused by an influenza virus. There are three types of influenza virus, type A, type B, and type C. Type A influenza virus are further segmented into subtypes depending on the combination on numerous virus surface proteins. Under the subtype of influenza A viruses, influenza A (H1N1) and A (H3N2) are presently propagated amongst the human race. Influenza viruses occur in every part of the world. On the other hand, the type C influenza virus solemnly occurs as compared to the type A and B. Hence, only type A and type B influenza viruses are in the list of seasonal influenza vaccines. Therefore, influenza vaccination is the most effective way to prevent an influenza infection.
To Request Sample Copy of This Report: https://www.qyresearchreports.us/check-discount/seasonal-influenza-vaccine-market-size-country-outlook-vaccination-analysis-pipeline-insights-clinical-trials-statement-deals-type-regulatory-price-trends-competitive-strategies-and-forecast2016-to-2022
The seasonal influenza vaccine market was predicted to reach more than US $4 billion while growing at a significant CAGR during the forecast period owing to several factors. In the past few years the influenza vaccine market has experienced a substantial growth owing to the fear of an imminent pandemic.The influenza vaccine market grew at a CAGR of nearly 65% between 2008 and 2010 because of the mayhem caused by the H1N1 virus. Nevertheless, the H1N1 flu vaccine demand will subside owing to the vanishing threat of swine flu epidemic. The increasing number of geriatric population and elevated prevalence of seasonal influenza outbreak contribute towards the positive growth of this industry’s market.Patent holders are getting secured by the intellectual property rights and hence the market share is constantly increasing. Yet, the budding patent expirations for superior influenza vaccines and the escalating popularity of influenza drugs as over-the-counter (OTC) components will be rendering an extra opportunity for the generic manufacturers. Factors such as restricted awareness pertaining to the availability latest vaccines, flimsy reimbursement facilities hinder the market growth of seasonal influenza vaccine market.
Some of the major and more promising vaccines are Fluzone High–Dose, FluzoneQuadrivalent, Intradermal (ID) Trivalent, Vaxigrip, FluarixQuadrivalent, FlulavalQuadrivalent, Fluenz Tetra, FluMistQuadrivalent, Flublok, VN–100, M–001, VAX–2012Q , TAK – 850, FlucelvaxQuadrivalent, AfluriaQuadrivalent, Agrippal, Fluad, Fluvirin, and Fluvax. Major market players of the seasonal influenza vaccine market are Sanofi, GlaxoSmithKline, Novartis, Abbott Laboratories, Mitsubishi Tanabe Pharma, Johnson & Johnson, Sinovac Biotech, Baxter International, F. Hoffmann-La Roche and AstraZeneca.
Seasonal influenza is a grave public health issue which causes serious illness and death in densely populated regions. It is an acute viral infection caused by an influenza virus. There are three types of influenza virus, type A, type B, and type C. Type A influenza virus are further segmented into subtypes depending on the combination on numerous virus surface proteins. Under the subtype of influenza A viruses, influenza A (H1N1) and A (H3N2) are presently propagated amongst the human race. Influenza viruses occur in every part of the world. On the other hand, the type C influenza virus solemnly occurs as compared to the type A and B. Hence, only type A and type B influenza viruses are in the list of seasonal influenza vaccines. Therefore, influenza vaccination is the most effective way to prevent an influenza infection.
